NRx Pharmaceuticals develops new proprietary formulation of HTX-100

NRx Pharmaceuticals announced that the company has developed a novel, proprietary formulation of IV Ketamine for use as HTX-100. This new formulation has the key advantage of achieving neutral pH, in contrast to the acidic pH of generic formulations of ketamine. Acidic substances are tolerated when diluted for intravenous use, but cause pain and may cause skin ulcers if administered subcutaneously. This patentable invention may enable the administration of ketamine in insulin pump-like devices in the clinic setting, eliminating the requirement for intravenous infusion personnel. NeuroRx previously executed a joint development agreement with a manufacturer of insulin pumps but has been awaiting a suitable, pH neutral formulation of ketamine. With this proprietary formulation, developed with partner Nephron Pharmaceuticals, NRx is expected to generate one or more patents, such as composition of matter or formulation. HTX-100 is expected to be marketed by HOPE Therapeutics, a wholly owned subsidiary of NRx.